Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
5.12
-0.08 (-1.54%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $51.50M in the quarter ending September 30, 2024, with 7.29% growth. This brings the company's revenue in the last twelve months to $201.21M, up 9.88% year-over-year. In the year 2023, Cytek Biosciences had annual revenue of $193.02M with 17.67% growth.
Revenue (ttm)
$201.21M
Revenue Growth
+9.88%
P/S Ratio
3.35
Revenue / Employee
$297,648
Employees
676
Market Cap
659.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
Dec 31, 2019 | 57.88M | 52.27M | 930.36% |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CTKB News
- 8 days ago - Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewsWire
- 16 days ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Upgrading Cytek Biosciences Stock On An Upcoming Catalyst - Seeking Alpha
- 7 weeks ago - Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025 - GlobeNewsWire
- 3 months ago - Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program - GlobeNewsWire
- 3 months ago - Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter - GlobeNewsWire